Peritoneal Surface Malignancy Treatment Mumbai – Dr. Chintamani Godbole
Peritoneal surface malignancy refers to cancers that involve the peritoneum, the thin lining of the abdominal cavity. For patients seeking Peritoneal surface malignancy treatment Mumbai, these cancers may develop in the peritoneum itself or spread from other organs, including the colon, appendix, stomach, ovary, or other parts of the abdomen. Because peritoneal cancer can involve multiple areas within the abdominal cavity, diagnosis and treatment often require specialized surgical assessment and a carefully planned multidisciplinary approach.
For patients seeking Peritoneal surface malignancy treatment Mumbai, Dr. Chintamani Godbole offers specialized expertise in colorectal and peritoneal oncology, including cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). His training in colorectal surgery and peritoneal malignancy surgery in India and the UK supports an individualized approach to patients with selected advanced abdominal cancers.
Understanding Peritoneal Surface Malignancy Treatment Mumbai
Peritoneal surface malignancy may occur when cancer cells spread across the peritoneal lining and form multiple deposits within the abdominal cavity. This condition is sometimes described as peritoneal carcinomatosis. Depending on the origin, extent, biology, and distribution of the cancer, treatment may involve systemic chemotherapy, surgery, HIPEC, or a combination of therapies.
Cytoreductive surgery aims to remove visible cancer deposits from the abdominal cavity. In selected patients, surgery may be followed by HIPEC, in which heated chemotherapy is circulated inside the abdomen to target microscopic cancer cells that may remain after visible disease has been removed.
The source treatment page specifically describes CRS followed by HIPEC for selected cancers involving the peritoneal cavity, including appendiceal cancer, pseudomyxoma peritonei, colon cancer, gastric cancer, ovarian cancer, and peritoneal mesothelioma.
What Is Cytoreductive Surgery?
Cytoreductive surgery, or CRS, is a specialized procedure designed to remove visible tumour deposits from the peritoneal cavity. Depending on where the cancer has spread, the operation may involve removing portions of the peritoneum or affected abdominal organs.
The extent of surgery varies from patient to patient. In some cases, removal of involved portions of the small or large intestine, gallbladder, spleen, or abdominal lining may be required to achieve adequate tumour clearance. The surgical plan is determined after evaluating the cancer’s location, spread, overall health, and suitability for treatment.
For someone exploring Peritoneal surface malignancy treatment Mumbai, understanding that CRS is different from conventional abdominal cancer surgery is important. Peritoneal disease was historically considered difficult to treat surgically in many cases; however, selected patients may be considered for cytoreductive surgery with or without HIPEC after detailed specialist assessment.
How Does HIPEC Work?
HIPEC stands for Hyperthermic Intraperitoneal Chemotherapy. It is generally performed after cytoreductive surgery when the visible tumour deposits have been removed as thoroughly as possible.
During HIPEC, a heated chemotherapy solution is circulated within the abdominal cavity. The treatment page states that the solution is maintained at approximately 42–43°C. The objective is to expose the abdominal cavity to chemotherapy and target microscopic malignant cells that may remain following surgery.
CRS and HIPEC are therefore complementary components of treatment in appropriately selected patients. CRS addresses visible disease, while HIPEC is intended to treat residual microscopic cancer cells.
Who May Be Considered for CRS and HIPEC?
Not every patient with peritoneal cancer is suitable for cytoreductive surgery and HIPEC. Careful patient selection is essential. The medical team may consider factors such as:
- The primary cancer and its biological characteristics
- The extent and distribution of peritoneal disease
- Whether the visible disease can be adequately removed
- Involvement of other abdominal organs
- Previous cancer treatments
- General health and ability to undergo major surgery
- Response to chemotherapy or other treatments
A specialist consultation helps determine whether surgery, systemic therapy, HIPEC, or another treatment strategy is appropriate.
Dr. Chintamani Godbole’s Expertise
Dr. Chintamani Godbole is a Colorectal Surgeon in Mumbai with a special interest in colorectal surgery and peritoneal surface oncology. His professional qualifications include MBBS, MS in General Surgery, DNB in Surgical Gastroenterology, MRCS and FRCS from the Royal College of Surgeons of Edinburgh.
His advanced training includes fellowship experience in minimally invasive colorectal surgery, colorectal cancer surgery, peritoneal cytoreductive surgery, and HIPEC in the UK. He was also a fellow at the Basingstoke Peritoneal Malignancy Institute, a specialist centre for colorectal and peritoneal cancer surgery.
According to his professional profile, Dr. Chintamani Godbole has more than 10 years of experience and has performed over 200 minimally invasive colorectal surgeries and more than 50 cytoreductive surgeries and HIPEC procedures for advanced peritoneal cancers.
His areas of expertise also include robotic and laparoscopic colorectal surgery, sphincter-preserving surgery for rectal cancer, trans-anal minimally invasive surgery, and surgery for inflammatory bowel disease.
Patient-Centred Care at Gadre Hospital
Treatment for advanced cancer can involve multiple consultations, investigations, surgery, hospitalisation, and follow-up. A clear communication process can help patients and families understand the diagnosis and proposed treatment pathway.
Dr. Chintamani Godbole’s profile highlights personalised direct communication with patients and relatives. His practice focuses on organ-specific colorectal cancer surgery and specialized treatment of colorectal and peritoneal conditions.
For patients considering Peritoneal surface malignancy treatment Mumbai, treatment is provided at Gadre Hospital in Dadar East, Mumbai. The hospital is located near Hindmata Cinema and serves as the clinical setting for consultations and surgical care associated with Dr. Chintamani Godbole’s practice.
Benefits and Risks of Cytoreductive Surgery with HIPEC
For appropriately selected patients, CRS combined with HIPEC may provide a treatment option for certain cancers that have spread within the abdominal cavity. The referenced treatment information notes that CRS and HIPEC can provide better survival outcomes than intravenous systemic chemotherapy alone in carefully selected cases.
However, CRS with HIPEC is a major surgical treatment and carries potential risks. These may include bleeding, infection, blood clots, enterocutaneous fistula, anastomotic leakage, nutritional or reduced calorie intake, and other complications associated with extensive abdominal surgery.
Patients should discuss potential benefits, risks, alternatives, expected hospital stay, and recovery with their treating surgical team before making treatment decisions.
Recovery After Cytoreductive Surgery and HIPEC
The duration of surgery and recovery can vary considerably according to the extent of disease and procedures performed. The referenced treatment page states that CRS with HIPEC may take approximately 6–10 hours and that hospitalisation may last around 7–10 days or longer depending on the cancer and individual circumstances.
Fatigue may continue for several weeks or months after major abdominal surgery. Gradual physical activity, adequate nutrition, follow-up appointments, wound care, and adherence to the surgical team’s instructions can support recovery.
Patients should remember that recovery timelines differ from one individual to another, particularly when extensive surgery or additional organ resections are required.
Why Consult a Specialist for Peritoneal Cancer?
Peritoneal malignancy can present complex surgical challenges because cancer deposits may be distributed across different areas of the abdominal cavity. A specialist with dedicated experience in colorectal and peritoneal oncology can evaluate whether a patient may be suitable for advanced treatment approaches such as CRS and HIPEC.
Patients searching for Peritoneal surface malignancy treatment Mumbai can discuss their diagnosis, imaging reports, previous treatments, and overall health with Dr. Chintamani Godbole to understand the available options. The treatment plan should be based on the individual’s cancer type, disease extent, medical condition, and multidisciplinary assessment.
Dr. Chintamani Godbole’s specialist training in colorectal and peritoneal oncology, together with his experience in cytoreductive surgery and HIPEC, forms an important part of his clinical practice.
Consult Dr. Chintamani Godbole for Peritoneal Cancer Care
If you or a family member has been diagnosed with peritoneal cancer or cancer that has spread within the abdominal cavity, timely specialist evaluation can help clarify the available treatment options. Peritoneal surface malignancy treatment Mumbai may involve complex procedures such as cytoreductive surgery and HIPEC in carefully selected patients.
Dr. Chintamani Godbole provides colorectal and peritoneal oncology consultations at Gadre Hospital, Mumbai, with expertise in advanced colorectal procedures, cytoreductive surgery, HIPEC, robotic surgery, and minimally invasive colorectal techniques.
+91 8108791470 | +91 8451865944 (In case of emergency)
drchintamanigodbole@gmail.com
Get Directions to the Clinic – Gadre Hospital, Mumbai
Frequently Asked Questions
1. What is cytoreductive surgery for peritoneal cancer?
Cytoreductive surgery is an extensive abdominal procedure performed to remove visible cancer deposits from the peritoneal cavity. In selected patients, it may be followed by HIPEC to treat microscopic cancer cells remaining after surgery.
2. Is HIPEC performed after cytoreductive surgery?
Yes. In the CRS-HIPEC approach, cytoreductive surgery is performed first to remove visible disease, followed by heated chemotherapy circulated within the abdominal cavity to target residual microscopic malignant cells.
3. What cancers can be treated with CRS and HIPEC?
Depending on the patient’s condition and suitability, CRS and HIPEC may be considered for selected cases of appendiceal cancer, pseudomyxoma peritonei, colon cancer, gastric cancer, ovarian cancer, and peritoneal mesothelioma.
4. How long does recovery take after CRS and HIPEC?
Recovery varies according to the extent of surgery and the patient’s overall condition. The referenced treatment information states that hospitalisation may last around 7–10 days or longer, while fatigue may continue for approximately 2–3 months.

Comments
Post a Comment